Every 8-K that ARTIVA BIOTHERAPEUTICS INC (ARTV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ARTV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARTV filings page.
Artiva Biotherapeutics, Inc. reported that on August 6, 2026 it issued a press release announcing its financial results for the quarter ended June 30, 2026. The press release is provided as Exhibit 99.1 and describes the company’s performance for that period.
The company explains that the information in this financial results press release, including Exhibit 99.1, is being furnished under the Exchange Act and is not deemed “filed” for purposes of Section 18 or automatically incorporated into other Securities Act or Exchange Act documents unless expressly stated. Artiva’s common stock trades on the Nasdaq Global Market under the symbol ARTV, and it is identified as an emerging growth company.
Artiva Biotherapeutics, Inc. set September 8, 2026 as the expected date for its 2026 annual meeting of stockholders, a date that falls more than 70 days after the one-year anniversary of the 2025 annual meeting. The company is an emerging growth company with common stock listed on the Nasdaq Global Market under the symbol ARTV.
Under its amended and restated bylaws and Exchange Act Rule 14a-8, stockholders must deliver notices of any business, director nominations, or proposals for inclusion in the proxy statement to the company's San Diego principal executive offices by the close of business on August 1, 2026.
Artiva Biotherapeutics announced several leadership changes and a new executive compensation package. On May 18, 2026, Diego Miralles, M.D. resigned from the Board and was appointed President and Head of Research and Development, reducing the Board size from eight to seven members. That same day, the company and Chief Financial Officer Thad Huston agreed to his separation, effective May 22, 2026; he will receive about $135,000 (three months of base salary) and up to nine months of COBRA health coverage under a separation agreement.
On the effective date, CEO Fred Aslan, M.D. was also appointed principal financial officer and principal accounting officer while remaining CEO and a director. Under an offer letter, Dr. Miralles will receive a $600,000 annual base salary, a discretionary annual bonus targeted at 45% of salary, options to purchase 232,500 shares, and 77,500 restricted stock units, all vesting over four years. The offer includes non–change-of-control and change-of-control severance protections that provide salary continuation, COBRA coverage, bonus eligibility and equity vesting acceleration if specified termination conditions are met.
Artiva Biotherapeutics, Inc. entered into an underwriting agreement to sell 23,871,526 shares of common stock at $11.52 per share and pre-funded warrants to purchase 2,170,138 shares at $11.5199 per warrant. The company expects gross proceeds of approximately $300.0 million from this offering.
The transaction is being conducted under an effective Form S-3 shelf registration, with closing expected on May 11, 2026, subject to customary conditions. The pre-funded warrants are exercisable at any time, subject to beneficial ownership limits generally set at 4.99% or 9.99%, adjustable up to 19.99% with 61 days’ prior notice.
Artiva Biotherapeutics reported a first-quarter 2026 net loss of $23.5 million as it advances its AlloNK cell therapy program for autoimmune diseases. Cash, cash equivalents and investments were $86.8 million as of March 31, 2026, down from $108.0 million at year-end 2025.
Initial refractory rheumatoid arthritis data from AlloNK plus rituximab showed a 71% ACR50 response rate at six months in a company-sponsored Phase 2a basket trial, with no patients relapsing or needing new immunomodulatory drugs. Across 55 autoimmune patients, no cytokine release syndrome or ICANS and a 2% rate of grade 3 or higher infections were reported.
The company has alignment with the FDA on conducting a single Phase 3 registrational randomized controlled trial in approximately 150 refractory RA patients, comparing AlloNK plus rituximab to rituximab alone, with ACR50 at six months as the primary endpoint. Trial initiation is planned for the second half of 2026 and a potential BLA submission is targeted for 2029.
Artiva Biotherapeutics reported a larger 2025 net loss as it advanced its AlloNK cell therapy program toward potential registrational development in refractory rheumatoid arthritis. Net loss was $83.9 million for 2025, compared with $65.4 million in 2024, driven mainly by higher research and development spending of $69.5 million and general and administrative expenses of $20.3 million.
The company ended 2025 with cash, cash equivalents and investments of $108.0 million, which it expects will fund operations into Q2 2027. AlloNK received FDA Fast Track designation in refractory RA, showed deep B-cell depletion and a favorable outpatient safety profile across multiple autoimmune diseases, and earlier oncology data in lymphoma demonstrated a 64% complete response rate with durable outcomes. Initial clinical response data in refractory RA and an FDA interaction on potential pivotal trial design are both anticipated in the first half of 2026.
Artiva Biotherapeutics appointed Thad Huston as Chief Financial Officer, effective February 18, 2026, making him the company’s principal financial and accounting officer. He brings more than 30 years of global finance and operational experience across large pharmaceutical, biotech and medical device companies.
Under his employment agreement, Huston will receive a base salary of $540,000 and will be eligible for an annual cash bonus targeted at 40% of base salary, with his 2026 bonus calculated as if he started on January 1, 2026. As an inducement to join, he will be granted 220,000 restricted stock units under the 2025 Inducement Plan, vesting over four years starting February 15, 2027, subject to continued employment and the filing of a Form S-8.
If terminated without cause or he resigns for good reason, Huston may receive salary continuation, COBRA benefits and partial equity vesting, with enhanced cash and full time-based equity acceleration if such a termination occurs in connection with a change of control, contingent on signing a release of claims.
Artiva Biotherapeutics, Inc. appointed Elaine Sorg as a Class I director, with her term running until the company’s 2028 annual meeting of stockholders. The Board acted on the recommendation of its Nominating and Corporate Governance Committee, and there are no related-party arrangements or transactions requiring disclosure.
Ms. Sorg brings more than 35 years of senior executive experience at major pharmaceutical companies, including roles as Senior Vice President and President of AbbVie’s U.S. commercial operations until her retirement in January 2024. She also serves on the board of CSL Limited, on Purdue University’s Dean’s Advisory Council, as a Senior Advisor at Boston Consulting Group, and on the Scientific Strategy Board of Galapagos.
Under Artiva’s Non-Employee Director Compensation Policy, she will receive an annual cash retainer of $40,000 and an initial option to purchase 27,500 shares of common stock, with one-third vesting shortly after grant and the remainder vesting monthly over two additional years, subject to continuous service. She is also eligible for automatic annual option grants to purchase 13,750 shares at each annual meeting, vesting over about one year, with all such options vesting in full upon a change in control, subject to the plan terms.
Artiva Biotherapeutics, Inc. implemented a one-time exchange program allowing a limited group of employees, including its President and CEO Fred Aslan and COO/CLO Jennifer Bush, to surrender underwater stock options for restricted stock units (RSUs) under the 2024 Equity Incentive Plan. The goal is to enhance retention and better align employee incentives with stockholders by replacing options with little current value.
Dr. Aslan surrendered options to purchase 869,136 shares of common stock and Ms. Bush surrendered options to purchase 84,877 shares. In return, they received RSUs equal to their surrendered vested and unvested options. For the RSUs issued in exchange for vested options, 50% will vest on August 15, 2026, and 25% will vest on each of November 15, 2026, and February 15, 2027, with full acceleration if they are terminated other than for Cause or resign for Good Reason. RSUs issued for unvested options will vest between August 15, 2026, and February 15, 2029, with an additional six months of vesting acceleration upon those same termination events.
Artiva Biotherapeutics (ARTV) disclosed initial safety and translational data for its investigational NK cell therapy AlloNK (AB-101) combined with rituximab or obinutuzumab in autoimmune diseases. As of October 1, 2025, 32 patients across refractory RA, Sjögren’s, systemic sclerosis, SLE and lupus nephritis were treated in outpatient settings, receiving 1B or 4B cells per dose. The regimen was generally well tolerated: no AlloNK-related Grade 3+ adverse events, no discontinuations, and no cytokine release syndrome, ICANS, GvHD or hypogammaglobulinemia; one hospitalization for an unrelated skin infection.
Translational findings showed all 23 analyzed patients had non-quantifiable peripheral CD19+ B cells by Day 13, corroborated by a high-sensitivity assay, with reconstitution patterns similar to CD19 auto-CAR-T. Artiva highlighted unmet need in refractory RA and plans to share initial clinical response data from >15 RA patients in H1 2026 and conduct FDA interactions in H1 2026 on a potential pivotal trial design.
Artiva Biotherapeutics filed a Form 8‑K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.
The company notes the information under Item 2.02, including Exhibit 99.1, is furnished and not filed, meaning it is not subject to Section 18 liability and is not incorporated into other filings unless expressly stated.